Clinical Trials
6 trialsNCT01689727 2023-06-22
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Subjects With Pituitary Tumors
Endocyte
Phase 2 Completed
NCT01915303 2020-09-18
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
Novartis
Phase 2 Terminated
NCT04335357 2020-04-06
TBR-760 in Adult Patients With Non-Functioning Pituitary Adenomas
Tiburio Therapeutics
Phase 2 Unknown
NCT01673646 2019-09-16
Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism
Novartis
Phase 2 Completed
NCT00958841 2016-07-26
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Novartis
Phase 2 Terminated
NCT01203618 2013-11-04
Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
Morphotek
Phase 2 Withdrawn